Document:

Exhibit 10.45

 

RESHAPE
LIFESCIENCES

EMPLOYMENT
AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(the “Agreement”) is made and entered on October 29, 2019 (the “Agreement Date”), between ReShape
Lifesciences, (“Company”), a Delaware corporation with its principal place of business at 1001 Calle Amanecer, San
Clemente, CA 92673; and Thomas Stankovich (“Employee”), a California resident whose address is 29011 Modjeska
Peak, Trabuco Canyon, CA 92679, for the purpose of setting forth the terms and conditions of Employee’s employment by Company.

 

WITNESETH:

 

WHEREAS,
the Company desires to employ Employee as the Chief Financial Officer of the Company, and for Employee to hold such position, on
the terms and conditions, and for the consideration, hereinafter set forth and Employee desires to be employed by the Company and
hold such position on such terms and conditions and for such consideration; and

 

WHEREAS,
Employee executed a Nondisclosure and Noncompetition Agreement with the Company on October 29, 2019 (“Nondisclosure
and Noncompetition Agreement”), which is attached as Exhibit A to this Agreement and fully incorporated herein.

 

NOW,
THEREFORE, for and in consideration of the mutual promises, covenants and obligations contained herein, the Company
and Employee agree as follows:

 

ARTICLE I

EMPLOYMENT, TERM AND DUTIES

 

1.1.       Employment.
Effective on the Agreement Date, Employee will be employed as the Company’s Chief Financial Officer. Employee accepts such
employment and agrees to perform services for the Company pursuant to the terms and conditions set forth in this Agreement.

 

1.2.       Term.
The term of this Agreement shall commence on the Agreement Date and, unless earlier terminated in accordance with Article III
of this Agreement, shall terminate one year from the Agreement Date (the “Term”); provided, however, that the Term
of this Agreement shall automatically renew for successive one-year terms thereafter unless, at least 90 days before the expiration
of the initial Term or any additional Term, either party provides written notice to the other of its or his desire to terminate
this Agreement.

 

1.3.         Position
and Duties.

 

1.3.1       Service
with Company. During the Term, Employee agrees to perform such duties and responsibilities as are assigned to him from time
to time by Company’s Chief Executive Officer (the “CEO”) and/or Board of Directors (the “Board).

 

1.3.2       Performance
of Duties. During the Term, Employee agrees to serve Company in an executive capacity as its Chief Financial Officer or such
other position as the Company may assign, and shall perform such duties as are required by the CEO and/or the Board.

 

     

     

    

(a)       Employee
shall at all times be subject to, and shall abide by, the policies established by the Company, including but not limited to the
policies set forth in the Company’s employee handbook, as it may be updated from time to time.

 

(b)       Employee
agrees that to the best of his ability and experience he will at all times loyally and conscientiously perform all of the duties
and obligations required of him either expressly or implicitly by the terms of this Agreement and that may be assigned to him in
accordance with this Agreement.

 

ARTICLE II

COMPENSATION, BENEFITS AND EXPENSES

 

2.1.           Base
Salary. Subject to the provisions of Article III of this Agreement, during the Term, Company shall pay Employee a “Base
Salary” of $300,000.00 on an annualized basis or such other rate as may from time to time be approved by the Board and/or
Company. Such Base Salary shall be paid in substantially equal regular periodic payments, less deductions and withholdings, in
accordance with Company’s regular payroll procedures, policies and practices, as such may be modified from time to time.
The Base Salary shall be reviewed by the Board annually for potential adjustment on the basis of performance; and Employee shall
be eligible, at Company’s sole discretion, for annual salary changes consistent with Company’s procedures, policies
and practices. If Employee’s Base Salary is increased from time to time during the Term, the increased amount shall become
the Base Salary for the remainder of the Term and any extensions of the Term and for as long thereafter as required pursuant to
Article III as applicable, subject to any subsequent increases.

 

2.2.           Incentive
Compensation. In addition to Base Salary, Company may make Employee eligible for cash or equity awards pursuant to Company’s
Incentive Compensation Plan, if any, as may be applicable and adopted by Company. Except to the extent as otherwise provided in
Article III in connection with a termination of Employee’s employment, payment of incentive compensation will be subject
to Employee achieving certain objectives set annually by the CEO and/or the Board of Directors (the “Board”), with
the target amount of any cash incentive compensation for any calendar year to be approved by the Board, which target in no event
shall be more than 30% (subject to performance of the specified objectives) of Employee’s Base Salary in effect from time
to time; provided, the 2019 cash incentive compensation will be pro-rated based on Employee’s employment with the Company
from the Agreement Date to December 31, 2019. Company shall pay any such incentive compensation for which Employee may be
eligible for a calendar year on or before March 15 of the following year (provided that Employee is employed on such date).
Employee will not be entitled to receive incentive compensation for any calendar year in which Employee’s employment is terminated,
except as may be provided in Article III.

 

2.3.           Non-Qualified
Stock Option Award. Company will grant Employee a non-qualified stock option under the Company’s 2019 Employee Inducement
Incentive Award Plan (the “Incentive Award Plan”) to purchase 1.25% shares of the Company’s common stock at
an exercise price per share equal to the Fair Market Value (as defined in the Incentive Award Plan) of one share of common stock
on the date of grant, subject to and contingent upon the approval of the Company’s board of directors, the terms of which
will be governed by the Incentive Award Plan and a non-qualified stock option award agreement to be executed in connection with
such grant which will include, among other terms, that such award will vest twenty five percent (25%) at the first anniversary
of the Agreement Date and 2.0833% per month thereafter.

 

    2

     

    

2.4.           Participation
in Benefits. During the Term of Employee’s employment by Company, Employee shall be entitled to participate in the employee
benefits offered generally by Company to its employees, to the extent that Employee’s position, tenure, salary, health and
other qualifications make Employee eligible to participate. Employee is eligible to receive vacation benefits in accordance with
the Company’s “Paid Time Off’ policy. Employee’s participation in such benefits shall be subject to the
terms of the applicable plans, as the same may be amended from time to time. Company does not guarantee the adoption or continuance
of any particular employee benefit during Employee’s employment; and nothing in this Agreement is intended to, or shall
in any way restrict the right of Company to amend, modify or terminate any of its benefit plans during the Term of this Agreement.

 

ARTICLE III

TERMINATION AND COMPENSATION FOLLOWING TERMINATION

 

3.1.           Termination.
Subject to the respective continuing obligations of the parties under this Agreement, this Agreement and Employee’s
employment hereunder may be terminated as of the applicable date, whether before or at the end of the Term (the “Separation
Date”) under any of the following circumstances:

 

3.1.1         Termination
by Mutual Agreement. By mutual written agreement of the parties at any time, which may specify a Separation Date.

 

3.1.2         Termination
by Employee’s Death. If Employee dies during the Term, the date of his death shall be his Separation Date.

 

3.1.3         Termination
Due to Employee’s Disability. If Employee becomes Disabled, the Separation Date shall be the effective date of his resignation
or his discharge by the Company because of the Disability, after engaging in a good faith interactive process, whichever occurs
first. For purposes of this Agreement, “Disabled” or “Disability” means the incapacity or inability of
Employee, whether due to accident, sickness or otherwise, to perform the essential functions of Employee’s position under
this Agreement, with or without reasonable accommodation (provided that no accommodation that imposes undue hardship on Company
will be required).

 

To the extent Employee
is unable to perform the essential functions of his position for more than 90 days during any period of 180 consecutive days, the
parties agree that he will be put on an unpaid leave of absence as a reasonable accommodation, and that the Company need not guarantee
reinstatement when Employee is released back to work as holding his job open at that time would be an undue hardship. Any disputes
over this Section shall be resolved by the parties in Arbitration under Section 4.5.

 

    3

     

    

3.1.4       Termination
by Company for Cause. Company may terminate this Agreement and Employee’s employment for Cause immediately upon written
notice to Employee. For purposes of this Agreement, “Cause” means: (a) willful breach of Employee’s duties
to Company or willful breach of this Agreement; (b) Employee’s conviction of any felony or any crime involving fraud,
dishonesty, or moral turpitude; (c) Employee’s willful participation in any fraud against or affecting Company or any
subsidiary, affiliate, customer, supplier, client, agent, or employee thereof; or (d) any other act that Company reasonably
determines constitutes gross or willful misconduct materially detrimental to Company including, but not limited to, unethical practices,
dishonesty, disloyalty, or any other acts harmful to Company; provided, however that a for Cause termination pursuant to clause
(a), if susceptible of cure, which determination is in the sole discretion of Company to make, shall not become effective unless
Employee fails to cure such failure to perform or breach within 30 days after his receipt of written notice from Company, such
notice to describe such failure to perform or breach and identity what reasonable actions shall be required to cure such failure
to perform or breach.

 

For purposes of this
Section 3.1.4, no act, or failure to act, on Employee’s part shall be considered “dishonest” or “willful”
unless done, or omitted to be done, by Employee in bad faith and without reasonable belief that his action or omission was in or
not opposed to, the best interest of Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly
adopted by the Board or based upon the advice of counsel for Company shall be conclusively presumed to be done, or omitted to be
done, by Employee in good faith and in the best interests of Company. Furthermore, the term “Cause” shall not include
ordinary negligence or failure to act, whether due to an error in judgment or otherwise, if Employee has exercised substantial
efforts in good faith to perform the duties reasonably assigned or appropriate to his position.

 

3.1.5      Termination
by Employee without Good Reason. Employee may at any time voluntarily terminate his employment under this Agreement, for any
reason or no reason, with 30 days’ written notice.

 

3.1.6      Termination
by Company without Cause. Company may terminate Employee’s employment under this Agreement at any time for any reason
or no reason with 30 days’ written notice, except that no notice shall be required for a termination without Cause following
a “Change in Control” as defined in Employee’s Non-Incentive Stock Option Agreement(s), as the case may be, with
Company (collectively, the “Stock Option Agreements”).

 

3.1.7       Termination
by Employee for Good Reason. Employee may at any time voluntarily terminate his employment pursuant to this Agreement for Good
Reason (as defined below); provided, however, that any resignation by Employee for Good Reason shall not be effective unless and
until the following two conditions have been satisfied: (a) he has notified Company in writing of the facts that he believes
constitute Good Reason, within 90 days after such facts first becomes known to him; and (b) Company fails to cure such Good
Reason within 30 days after its receipt of that notice. Employee’s resignation shall be effective before the end of that
30-day period as of any earlier date on which Company refuses to cure or denies the existence of such Good Reason. The effective
date of any resignation for Good Reason shall be a Separation Date. If Company timely cures such Good Reason, or it is determined
that the reason for Employee’s resignation was not a Good Reason, he shall be deemed not to have resigned unless he elects
to resign under Section 3.1.5.

 

    4

     

    

For purposes of this
Agreement, “Good Reason” means, at any time: (a) the assignment by Company to Employee of employment duties, functions
or responsibilities that are significantly different from, and result in a material diminution of, Employee’s duties, functions
or responsibilities; (b) a material reduction in Employee’s Base Salary or the minimum target amount provided under
Section 2.2 for his cash incentive compensation for any calendar year of more than 50%; or (c) a Company requirement
that Employee be based at any office or location more than 50 miles from Employee’s primary work location before the date
of this Agreement.

 

3.1.8       Termination
at End of Term. The termination of this Agreement and Employee’s employment, as of the end of the initial Term or any
additional Term, pursuant to the operation of the provisions of Section 1.2, shall entitle Employee only to the payments provided
in Sections 3.2.1 and 3.3.

 

3.2.         Compensation
following Termination of Employment. If Employee’s employment pursuant to this Agreement is terminated before the end
of the Term, or by Company as of the end of the Term, Employee shall be entitled to the following compensation and benefits upon
such termination:

 

3.2.1       Payment
of Base Salary. If Employee’s employment is terminated pursuant to any subsection of Section 3.1, Company shall,
within 14 calendar days following the Separation Date, pay to Employee, Employee’s surviving spouse (or, if none, Employee’s
estate), as the case may be, any amounts due to Employee for Base Salary through the Separation Date.

 

If a termination occurs
pursuant to Section 3.1.5 (by Employee without Good Reason), when Company receives Employee’s notice Company shall have
the option, at its discretion (a) to continue to engage Employee’s services through the 30 day notice period until the
Separation Date, or (b) terminate the use of Employee’s services during the 30 day notice period before the Separation
Date but treat Employee as if he were providing services through the 30 day notice period until the Separation Date for purposes
of determining Employee’s compensation due him pursuant to this Section 3.2.1.

 

3.2.2       Payment
of Severance for Termination by Company without Cause or by Employee for Good Reason. If (a) Employee’s employment
is terminated pursuant to either of Sections 3.1.6 (by Company without Cause) or 3.1.7 (by Employee for Good Reason), (b) Employee
has executed and delivered to Company, within 60 days after the effective date of that termination, a written release in substantially
the same form as is attached hereto as Exhibit B, and (c) the rescission period specified therein has expired, Company
shall, subject to any payment delay required by Section 3.2.6, continue to pay, as severance pay, Employee’s Base Salary
(at the rate in effect on the Separation Date) for a period of six (6) months following the Separation Date. To the extent
that Employee has received stock options or other equity awards, the terms of such stock options and/or the Company’s Stock
Incentive Plan shall determine the vesting of any Options or other equity awards upon termination under this Section 3.2.2.
Such payments of Base Salary will be at the usual and customary pay intervals of Company and will be subject to all appropriate
deductions and withholdings. For purposes of Employee’s qualification for severance pay, his right to any series of such
payments due under this Agreement is treated as the right to a series of separate payments, each of which is subject to all of
the requirements of this Section 3.2.2.

 

    5

     

    

3.2.3       Payment
of Severance at End of Term. If (a) Employee’s employment terminates pursuant to Section 3.1.8, (b) Employee
has executed and delivered to Company, within 60 days after the effective date of that termination, a written release in substantially
the same form as is attached hereto as Exhibit B, and (c) the rescission period specified therein has expired, Company
shall, subject to any payment delay required by Section 3.2.6, continue to pay, as severance pay, Employee’s Base Salary
at the rate in effect on the Separation Date, for a period of six months following the Separation Date. To the extent that Employee
has received stock options or other equity awards, the terms of such stock options and/or the Company’s Stock Incentive
Plan shall determine the vesting of any Options or other equity awards upon termination under this Section 3.2.3.

 

3.2.4       Effects
of Change in Control. Upon the occurrence of a Change in Control (as defined in the Stock Option Agreement), Company agrees
that, notwithstanding any contrary provisions of the Stock Option Agreements or Company’s Incentive Award Plan, the vesting
schedule of Employee’s stock options granted in the Stock Option Agreements (the “Options”) shall accelerate
such that on the date the Change in Control is completed, 100% of any then-unvested shares subject to the Options held by Employee
shall immediately vest; provided, however, that if, in connection with the consummation of the transaction resulting in the Change
in Control, Employee receives a cash payment with respect to each Option (after they become fully vested) equal to the difference
or “spread” between (a) the per share amount paid to holders of Company’s common stock in such transaction
and (b) the per share exercise price under the applicable Stock Option Agreement, his Options shall be cancelled upon the
consummation of the Change in Control in exchange for such cash payment.

 

3.2.5       General
Provision Regarding Treatment of Options. Except as otherwise specified in Sections 3.2.2 and 3.2.4 of this Agreement, the
terms of the Incentive Award Plan and Stock Option Agreements, as applicable, shall govern the treatment of the Options following
the Separation Date.

 

3.2.6       Potential
Delay of Severance Payments. If, as of the Separation Date, (a) Company’s common stock is publicly traded (as determined
under Code Section 409A), (b) Employee is a “specified employee” (as determined under Code Section 409A),
and (c) any portion of the severance pay due Employee under Sections 3.2.2, 3.2.3 would exceed the sum of the applicable limited
separation pay exclusions (or otherwise not qualify for any exclusion) as determined pursuant to Code Section 409A, then payment
of the excess amount shall be delayed until the first regular payroll date of Company following the six month anniversary of Employee’s
Separation Date (or the date of his death, if earlier than that anniversary), and shall include a lump sum equal to the aggregate
amounts that Employee would have received had payment of this excess amount commenced as provided in Sections 3.2.2 or 3.2.3 after
the Separation Date. If Employee continues to perform any services for Company (as an employee or otherwise) after the Separation
Date, such six month period shall be measured from the date of Employee’s “separation from service” as defined
pursuant to Code Section 409A. Each payment under this Agreement shall be treated as a separate payment for purposes of Code
Section 409A.

 

3.3.         Benefits
Following Certain Employment Terminations. Except as otherwise provided in this Section 3.3, the benefits to which Employee
(or, as applicable, Employee’s spouse, eligible dependents or estate) may be entitled upon termination of his employment,
pursuant to the plans and policies of Company described in Article II of this Agreement, shall be determined and paid in
accordance with such plans, policies and applicable laws.

 

    6

     

    

3.3.1       COBRA
Reimbursements Following Certain Employment Terminations. If Employee’s employment is terminated pursuant to any of Section 3.1.2,
Section 3.1.3, Section 3.1.6, Section 3.1.7 or Section 3.1.8, subject to Employee’s execution and non-revocation
of the Release, if Employee timely and effectively elects continuation coverage under Company’s group health plans pursuant
to section 4980B of the Code, as amended (“COBRA”) or similar state law, Company will pay or reimburse the premiums
for such coverage of Employee (and Employee’s dependents, as applicable) at the same rate it pays for active employees for
a period of 6 months from the Separation Date; provided, however, that Company’s obligation to make such payments shall immediately
expire if Employee ceases to be eligible for continuation coverage under COBRA or similar state law or otherwise terminates such
coverage or, if earlier, the date Employee becomes eligible for group health plan coverage with a new employer of Employee.

 

3.4.         Surrender
of Records and Property. Upon termination of Employee’s employment with Company, Employee shall deliver promptly to Company
all Confidential Information as defined in the Nondisclosure and Noncompetition Agreement attached at Exhibit A, and all Company
property including, but not necessarily limited to records, manuals, books, blank forms, documents, letters, memoranda, business
plans, minutes, notes, notebooks, reports, computer disks, computer software, computer programs (including source code, object
code, on-line files, documentation, testing materials and plans and reports), computer print-outs, member or customer lists, credit
cards, keys, identification, products, access cards, designs, drawings, sketches, devices, specifications, formulae, data, tables
or calculations or copies thereof, and all other tangible or intangible property relating in any way to the business of Company
that are the property of Company or any subsidiary or affiliate, if any, or which relate in any way to the business, products,
practices or techniques of Company or any subsidiary or affiliate.

 

3.6          Code
Section 409A. Notwithstanding anything to the contrary in this Agreement, Employee will experience a termination of employment
with the Company only if such termination also constitutes a “separation from service” as defined under Code Section 409A.
The payment and benefits provided under this Article III are intended to be exempt from, or comply with, the requirements
of Code Section 409A and this Agreement will be construed and administered to give effect to such intent.

 

ARTICLE IV

MISCELLANEOUS PROVISIONS

 

4.1.         Company
Remedies. Employee acknowledges and agrees that the restrictions and agreements contained in this Agreement and in the Nondisclosure
and Noncompetition Agreement that is attached as Exhibit A to this Agreement are reasonable and necessary to protect legitimate
interests of Company; that any violation of the Nondisclosure and Noncompetition Agreement would be highly injurious to Company;
that Employee’s violation of the Nondisclosure and Noncompetition Agreement would cause Company irreparable harm that would
not be adequately compensated by monetary damages; and that the remedy at law for any breach of any of the provisions of the Nondisclosure
and Noncompetition Agreement will be inadequate.

 

    7

     

    

4.2.           Assignment.
This Agreement shall not be assignable, in whole or in part, by Employee without the written consent of Company and any purported
or attempted assignment or transfer of this Agreement or any of Employee’s duties, responsibilities or obligations hereunder
shall be void. This Agreement shall inure to the benefit of and be binding upon Employee, Employee’s heirs and personal
representatives. This Agreement shall inure to the benefit of and be binding upon Company and its successors and assigns. Notwithstanding
the foregoing, Company may not, without the written consent of Employee, assign its rights and obligations under this Agreement
to any business entity that has become the successor to Company in the event of a sale, merger, liquidation or similar transaction.
After any such assignment by Company to which Employee has given such consent, Company shall be discharged from all further liability
hereunder and such successor assignee shall thereafter be deemed to be Company for the purposes of all provisions of this Agreement.

 

4.3.           Notices.
All notices, requests, demands and other communications under this Agreement shall be in writing, shall be deemed to have been
duly given on the date of service if personally served on the parties to whom notice is to be given, or on the third day after
mailing if mailed to the parties to whom notice is given, whether by first class, registered, or certified mail, and properly addressed
as follows:

 

	If to Company, at:	ReShape Lifesciences 
1001 Calle Amanecer 
San Clemente, CA 92673	

	 	 
	If to Employee, at:	Thomas Stankovich 
29011 Modjeska Peak 
Trabuco Canyon, CA 92679	

 

Any party may change the address for the
purpose of this Section by giving the other written notice of the new address in the manner set forth above.

 

4.4.           Governing
Law/Venue. The validity, interpretation, performance and enforcement of this Agreement shall be governed by the laws of the
State of California, without regard to conflicts of laws principles thereof. The parties irrevocably consent and agree that the
venue of any cause of action seeking injunctive relief shall be California District Court, Orange County, and the parties further
irrevocably consent to the personal jurisdiction of the California District Court for any such action.

 

4.5.           Mediation
and Arbitration. Employee and the Company agree that any and all disputes regarding this Agreement or Employee’s employment
with the Company will first be addressed in mediation before a mutually agreeable mediator, paid for by the Company. If the matter
cannot be resolved in mediation, then the dispute will be resolved in binding arbitration administered by JAMS pursuant to its
Employment Arbitration Rules then in effect (available at www.jamsadr.com and upon request). The arbitration shall take place
in San Clemente, California before an experienced employment arbitrator licensed to practice law in California and mutually selected
by the parties. The arbitrator may not modify or change this Agreement in any way. All out-of-pocket costs of the arbitration,
including the fees of the arbitrator, the costs of any record or transcript of the arbitration, administrative fees, and other
fees and costs shall be paid for by the Company. Each party shall initially be responsible for his/its own attorneys’ fees,
except that the arbitrator may award such fees and costs, exclusive of the arbitrator’s fees, to the prevailing party in
a manner consistent with applicable law as set forth in Paragraph 4.12. All procedural and substantive rights that the Employee
and the Company would have in a court of law, will be extended to the parties in arbitration, including full discovery, the application
of the Federal Rules of Evidence, and all forms of relief. The parties expressly acknowledge that they are waiving any right
they may have to a jury trial for any and all claims covered by this Agreement.

 

    8

     

    

(a)       Class Action
Waiver. Except as otherwise required under applicable law, the Company and Employee expressly intend and agree as follows:
(1) that class action and representative action procedures shall not be asserted, nor will they apply, in any arbitration
pursuant to this Agreement; (2) that neither the Company nor Employee will assert, participate in, or join class action or
representative action claims against the other in arbitration or otherwise; and (3) that the Company and Employee shall only
submit their own, individual claims in arbitration and will not seek to represent the interests of any other person.

 

4.6.           Construction.
Notwithstanding the general rules of construction, both Company and Employee acknowledge that both parties were given
an equal opportunity to negotiate the terms and conditions contained in this Agreement, and agree that the identity of the drafter
of this Agreement is not relevant to any interpretation of the terms and conditions of this Agreement.

 

To the extent any provision of this Agreement
may be deemed to provide a benefit to Employee that is treated as non-qualified deferred compensation pursuant to Code Section 409A,
such provision shall be interpreted in a manner that qualifies for any applicable exemption from compliance with Code Section 409
or, if such interpretation would cause any reduction of benefit(s), such provision shall be interpreted (if reasonably possible)
in a manner that complies with Code Section 409A and does not cause any such reduction.

 

4.7.           Severability.
In the event any provision of this Agreement (or portion thereof) shall be held illegal or invalid for any reason, said illegality
or invalidity shall not in any way affect the legality or validity of any other provision of this Agreement. To the extent any
provision (or portion thereof) of this Agreement shall be determined to be invalid or unenforceable in any jurisdiction, such
provision (or portion thereof) shall be deemed to be deleted from this Agreement as to such jurisdiction only, and the validity
and enforceability of the remainder of such provision and of this Agreement shall be unaffected.

 

4.8.           Entire
Agreement. This Agreement, including the Nondisclosure and Noncompetition Agreement that is attached as its Exhibit A
and fully incorporated herein, is the final, complete and exclusive agreement of the parties and sets forth the entire agreement
between Company and Employee with respect to Employee’s employment by Company, and there are no undertakings, covenants
or commitments other than as set forth herein. The Agreement may not be altered or amended, except by a writing executed by Employee
and a member of the Board. This Agreement supersedes, terminates, replaces and supplants any and all other prior understandings
or agreements between the parties relating in any way to the hiring or employment of Employee by Company.

 

4.9.           Survival.
The parties expressly acknowledge and agree that the provisions of this Agreement that by their express or implied terms extend
beyond the expiration of this Agreement or the termination of Employee’s employment under this Agreement, shall continue
in full force and effect, notwithstanding Employee’s termination of employment under this Agreement or the expiration of
this Agreement.

 

    9

     

    

4.10.       Waivers.
No failure on the part of either party to exercise, and no delay in exercising, any right or remedy under this Agreement shall
operate as a waiver thereof; nor shall any single or partial exercise of any right or remedy under this Agreement preclude any
other or further exercise thereof or the exercise of any other right or remedy granted hereby or by any related document or by
law.

 

4.11.       Attorneys’
Fees for Resolving Disputes. If any party to this Agreement is made or shall become a party to any litigation (including arbitration)
commenced by or against the other party involving the enforcement of any of the rights or remedies of such party, or arising on
account of a default of the other party in its performance of any of the other party’s obligations hereunder, then the prevailing
party in such litigation shall be entitled to receive from the other party all costs incurred by the prevailing party in such
litigation, plus reasonable attorneys’ fees to be fixed by the court or arbitrator (as applicable), with interest thereon
from the date of judgment or arbitrator’s decision at the rate of 8% or, if less, the maximum rate permitted by law.

 

[Signature Page Follows]

 

    10

     

    

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	 	ReShape Lifesciences
	 	 
	 	By:	/s/ Barton P. Bandy
	 	Its:	CEO
	 	 
	 	/s/ Thomas Stankovich
	 	 Thomas Stankovich

 

    

     

    

 

Exhibit A

ReShape Lifesciences Inc.

 

Nondisclosure and Non-Solicitation Agreement

 

This is an agreement between Thomas Stankovich
( “Employee” ) and ReShape Lifesciences Inc., its affiliates, successors and assigns (“Employer”). The
parties agree that Employer would be substantially harmed if Employee competes with Employer during employment with Employer or
after termination of employment with Employer. The parties further agree that Employer would be substantially harmed if Employee
were to disclose its Confidential, Proprietary and Trade Secret Information.

 

Therefore, in consideration of Employer’s
employment of Employee for monetary compensation, benefits, access to Employer’s Trade Secrets and/or Confidential Information,
and/or other valuable consideration provided by Employer, Employee agrees as follows:

 

		I.	Nondisclosure of Confidential, Proprietary, and Trade Secret Information

 

Employee agrees not to disclose Confidential
Information to any other third party or company, other than in connection with Employee’s employment with Employer, or use
such information, directly or indirectly, for any purpose whatsoever, without the prior written consent of Employer.

 

For purposes of this Agreement, “Confidential
Information” means any information that is not generally known to the public or to other persons who can obtain economic
value from its disclosure or use; information which derives independent economic benefit from not being known to such persons;
and information about the activities or business of Employer that is not generally known to others engaged in similar business
or activities, its products, services, finances, trade secrets, contracts, patents filed or pending, the techniques used in completing
customer projects, research and development, data and information, processes, designs, engineering, marketing plans or techniques,
organization or operation. The foregoing list is intended to be illustrative rather than comprehensive. Additionally, the term
 “confidential information” shall mean any confidential information as that term is defined in any Agreement Employer
may have with its customers or other third parties from time to time.

 

    A-1

     

    

		II.	Assignment of Inventions

 

		A)	Disclosure and Assignment of Inventions and Other Works. During the term of this Agreement
and for one year following the Separation Date, Employee shall promptly disclose to Employer in writing all ideas, improvements
and discoveries, whether or not such are patentable or copyrightable, and whether or not in writing or reduced to practice (“Inventions”)
and any writings, drawings, diagrams, charts, tables, databases, software (in object or source code and recorded on any medium),
and any other works of authorship, whether or not such are copyrightable (“Works of Authorship”) that are conceived,
made, discovered, written or created by Employee alone or jointly with any person, group or entity, whether during the normal hours
of his employment at Employer or on Employee’s own time. Employee hereby assigns all rights to all such Inventions and Works
of Authorship to Employer. Employee shall give Employer all the assistance it reasonably requires for Employer to perfect, protect,
and use its rights to such Inventions and Works of Authorship. Employee shall sign all such documents, take all such actions and
supply all such information that Employer considers necessary or desirable to transfer or record the transfer of Employer’s
entire right, title and interest in such Inventions and Works of Authorship and to enable Employer to obtain exclusive patent,
copyright, or other legal protection for Inventions and Works of Authorship anywhere in the world, provided Employer shall bear
all reasonable expenses of Employee in rendering such cooperation.

 

		B)	Prior Inventions. Employee has set forth on Exhibit A attached hereto a list of all
significant Inventions, to the best of his knowledge, that Employee has, alone or jointly with others, made prior to his employment
with Employer that Employee considers to be Employee’s property or the property of third parties and that Employee wishes
to exclude from the scope of this Agreement (collectively referred to as “Prior Inventions”). If no such disclosure
is attached, or permission supporting evidence is available, Employee represents that there are no Prior Inventions. If, during
Employee’s employment with Employer, Employee incorporates a Prior Invention into an Employer product or process, Employer
is hereby granted a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple
tiers of sublicenses) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, Employee agrees
that Employee will not incorporate, or permit to be incorporated, Prior Inventions in any Employer Inventions without Employer’s
prior written consent.

 

		C)	Notice and Acknowledgment. In accordance with California Statutes, the foregoing paragraph
does not require Employee to assign or offer to assign to Employer any of Employee’s rights in an Invention that Employee
developed entirely on Employee’s own time without using Employer’s equipment, supplies, facilities or trade secret
information, and (a) that does not relate directly to Employer’s business or to Employer’s actual or demonstrably
anticipated research or development, or (b) that does not result from any work performed by Employee for Employer. For the
purpose of this Section, “Employer’s business” shall be defined as development pertaining to implantable medical
devices to treat obesity or devices to apply signals to a vagus nerve to treat a gastrointestinal disorder (e.g., obesity, pancreatitis
or irritable bowel syndrome).

 

To the extent a provision in this
Agreement purports to require Employee to assign Inventions otherwise excluded by this paragraph, the provision is against the
public policy of the State of California and is unenforceable. By signing this Agreement, Employee acknowledges receipt of the
notification required by California Statutes.

 

    A-2

     

    

		III.	Non-Solicitation of Employees

 

Employee hereby acknowledges that Employer’s
employees, consultants and other contractors constitute vital and valuable aspects of its business and missions on a worldwide
basis. In recognition of that fact, for a period of one year following the termination of this Agreement for any reason whatsoever,
Employee shall not solicit, or assist anyone else in the solicitation of, any of Employer’s then-current employees, consultants
and other contractors to terminate their respective relationships with Employer and to become employees, consultants and other
contractors of any enterprise with which Employee may then be associated, affiliated or connected.

 

		IV.	Employer Remedies

 

Employee acknowledges and agrees that the
restrictions and agreements contained in this Agreement are reasonable and necessary to protect legitimate interests of Employer,
that the services to be rendered by Employee are of a special, unique and extraordinary character, that it would be difficult to
replace such services, that any violation of this Agreement would be highly injurious to Employer, Employee’s violation of
any provision of this Agreement would cause Employer irreparable harm that would not be adequately compensated by monetary damages,
and that the remedy at law for any breach of this Agreement will be inadequate. Accordingly, Employee specifically agrees that
Employer shall be entitled, in addition to any remedy at law, to preliminary and permanent injunctive relief and specific performance
for any actual or threatened violation of this Agreement and to enforce the provisions of this Agreement. Should a breach of the
agreement occur, Employer will be entitled to recover costs, including attorney’s fees, incurred in enforcing the terms of
the Agreement for each breach. If a Court finds any part of the Agreement to be invalid, the remainder of the provisions shall
remain in full force and effect to the extent possible.

 

		V.	Governing Law/Venue

 

The validity, interpretation, performance
and enforcement of this Agreement shall be governed by the laws of the State of California, without regard to conflicts of laws
principles thereof. The parties irrevocably consent and agree that the venue of any cause of action seeking injunctive relief shall
be California District Court, Orange County, and the parties further irrevocably consent to the personal jurisdiction of the California
District Court for any such action.

 

		VI.	Construction

 

Notwithstanding the general rules of
construction, both Employer and Employee acknowledge that both parties were given an equal opportunity to negotiate the terms and
conditions contained in this Agreement, and agree that the identity of the drafter of this Agreement is not relevant to any interpretation
of the terms and conditions of this Agreement.

 

		VII.	Severability

 

In the event any provision of this Agreement
(or portion thereof) shall be held illegal or invalid for any reason, said illegality or invalidity shall not in any way affect
the legality or validity of any other provision of this Agreement. To the extent any provision (or portion thereof) of this Agreement
shall be determined to be invalid or unenforceable in any jurisdiction, such provision (or portion thereof) shall be deemed to
be deleted from this Agreement as to such jurisdiction only, and the validity and enforceability of the remainder of such provision
and of this Agreement shall be unaffected.

 

    A-3

     

    

		VIII.	Waiver

 

Failure by Employer to enforce any provision
of this Agreement will not constitute a waiver of or a prohibition against any further enforcement of that provision or any other
provision of this Agreement.

 

		IX.	Entire Agreement and Amendment

 

This Agreement supersedes all previous
agreements between the parties concerning the subject matter of this Agreement. All amendments to this Agreement must be in writing
and signed by the parties to be effective.

 

		X.	At Will Employment

 

This Agreement is not an employment agreement
for any specified period of time and Employee understands that either Employee or Employer may terminate the employment relationship
at any time and for any reason or no reason at all.

 

		XI.	Succession and Survival

 

This Agreement and the rights, duties and
obligations of this Agreement shall survive the termination of Employee’s employment with Employer and shall inure to the
benefit of and shall be binding upon Employee’s heirs, assigns and personal representatives and the successors of Employer.

 

    A-4

     

    

	Executed this 7th day of November 2019.	 
	 	 
	EMPLOYEE	 
	 
	By:	/s/ Thomas Stankovich	 
	Printed Name:	Thomas Stankovich	 
	 	 	 
	RESHAPE LIFESCIENCES INC.	 
	 
	By:	/s/ Barton P. Bandy	 
	Printed Name:	 Barton P. Bandy	 
	Its:	CEO	 

 

    A-5

     

    

	To:	ReShape Lifesciences Inc.	 
	 	 
	From:	Thomas Stankovich	 
	 	 
	Date:	11/7/19	 
	 	 
	Subject:	Prior Inventions	 
	 	 

		1.	Except as listed in Section 2 below, the following is a complete list of all inventions or
improvements relevant to the subject matter of my employment by ReShape Lifesciences, Inc. (“Employer”) that have
been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Employer :

 

x
No inventions or improvements.

 

 ̈
See below:

 

		 	 

 

		 	 

 

		 	 

 

 ̈
Additional sheets attached

 

		2.	Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1
above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with
respect to which I owe to the following parties:

 

	Invention or Improvement	 	Party(ies)	 	
        Relationship

	 	 	 	 	 
	1.	 	 	 	 	 
	 	 	 	 	 
	2.	 	 	 	 	 
	 	 	 	 	 
	3.	 	 	 	 	 

 

 ̈
Additional sheets attached.

 

    A-6

     

    

EXHIBIT B

CONFIDENTIAL
SEPARATION AGREEMENT AND GENERAL RELEASE

 

This Confidential
Separation Agreement and General Release (hereinafter “Agreement”) is entered into by and between                                      (hereinafter
 “you”) and ReShape Lifesciences Inc. (hereinafter “ReShape Lifesciences”).

 

WHEREAS,
you and ReShape Lifesciences entered into an Employment Agreement dated                                           (“Employment
Agreement”) which terminates effective                    ,
except as to certain provisions outlined below;

 

WHEREAS,
ReShape Lifesciences wishes to provide you with the separation benefits described in Section 2 below; and

 

WHEREAS,
you and ReShape Lifesciences want to fully and finally settle all issues, differences, and claims, whether potential or actual,
between you and ReShape Lifesciences, including, but not limited to, any claim that might arise out of your employment with ReShape
Lifesciences or the termination of your employment with ReShape Lifesciences;

 

NOW,
THEREFORE, in consideration of the provisions and of the mutual covenants contained herein, you and ReShape Lifesciences
agree as follows:

 

1.             Separation
from Employment. Effective                                      (your
 “date of separation”), your employment with ReShape Lifesciences terminates. Except as provided in this Agreement,
all benefits and privileges of employment end as of your date of separation.

 

2.             Separation
Benefits. As consideration for your promises and obligations under this Agreement, and subject to the terms and conditions
of this Agreement, including the release of claims set forth below, ReShape Lifesciences agrees to pay you, as separation pay,
the gross amount of                                     ,less
applicable deductions and withholdings for state and federal taxes, which amount represents six months of your base salary as of
your date of separation. The separation pay will be divided and paid to you in substantially equal periodic payments at the usual
and customary pay intervals of ReShape Lifesciences, less deductions and withholdings. The payments will begin within 30 business
days of the date on which ReShape Lifesciences receives this Agreement signed by you, provided that you do not revoke or rescind
this Agreement as set forth below. You agree that you are not entitled to the separation benefits provided to you in this Agreement
if you do not sign this Agreement.

 

3.             Incentive
Compensation. You are not entitled to receive incentive compensation for calendar year                        .

 

4.             Medical,
Dental, and Life Insurance. The benefits to which you (or, as applicable, your spouse and eligible dependents) may be entitled
upon termination of your employment shall be determined and paid in accordance with such plans, policies and applicable laws.

 

    B-1

     

    

5.             Stock
Options. All options to purchase shares of common stock of ReShape Lifesciences held by you (the “Options”) are
subject to the terms of one or more Stock Option Agreements between you and the Company (each, an “Option Agreement”)
and were granted pursuant to the ReShape Lifesciences Inc. 2019 Employee Inducement Incentive Award Plan, as amended (the “Plan”).
Pursuant to the terms and conditions set forth in the Option Agreements, ReShape Lifesciences agrees that, notwithstanding anything
to the contrary set forth in such Option Agreements or the Plan, during the two-year period following your date of separation,
you shall be permitted to exercise any Option immediately to the extent that such Option was vested as of your date of separation
or would have vested within one year of your date of separation had your employment with Company not terminated. Notwithstanding
anything to the contrary set forth in such Option Agreements or the Plan, ReShape Lifesciences shall have a right, following your
date of separation, to buy back all such Options based on the per share exercise price under the applicable Option Agreement.
The parties agree and acknowledge that, with respect to any Options that were intended by the parties to be treated as “incentive
stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, such Options, to
the extent they may be exercised by you more than 90 days following your date of separation, shall be treated as non-qualified
options, notwithstanding any provision in the Option Agreements to the contrary.

 

6.            Confidential
Information; Nonsolicitation. You executed an Employment Agreement with ReShape Lifesciences as well as a Nondisclosure and
Noncompetition Agreement, copies of which is attached hereto as Exhibit A. All provisions of both agreements, including those,
that by their terms, survive the termination of your employment will continue in full force and effect and are not negated or otherwise
affected by this Agreement, including but not limited to the Employment Agreement Section 4.1: Company Remedies; Section 4.4:
Governing Law/Venue; Section 4.5: Arbitration; and the Confidentiality and Non-Solicitation attached to the Employment Agreement
as its Exhibit A and fully incorporated therein.

 

7.            Return
of ReShape Lifesciences Property. You acknowledge that, on or before the date you sign this Agreement, you have returned all
ReShape Lifesciences property in your possession, including, but not limited to, all files, memoranda, documents, records, copies
of the foregoing, any ReShape Lifesciences credit card, computer, fax machine, Smartphone, printer, copier, keys, access cards,
and any other property of ReShape Lifesciences in your possession. You also acknowledge that, on or before the date you sign this
Agreement, you have provided ReShape Lifesciences with any and all pass codes and/or personal identification numbers used by you
to access the ReShape Lifesciences computer system, e-mail system, and/or the Internet, and/or documents or files contained on
and saved in the ReShape Lifesciences computer system.

 

8.            Duty
to Cooperate. You agree that, beginning on the date you are presented with this Agreement, you will cooperate with ReShape
Lifesciences with respect to the transition of your duties, the preservation of effective operations and customer service, and
ReShape Lifesciences’ strategic and commercial initiatives. As part of your agreement to cooperate, you will provide a list
identifying the status of major projects under way, pending customer interactions, the status of sale cycles with customers, the
names and contact information of key contacts at customers, and any other information reasonably requested by ReShape Lifesciences
regarding your duties and responsibilities. You further agree that, in the 30 day period following your acceptance of this Agreement
you will periodically make yourself accessible and available during normal business hours for consultation with ReShape Lifesciences
representatives in connection with the transition of your duties and responsibilities. You agree that such consultation may include
appearing from time to time at the office of ReShape Lifesciences for conferences.

 

    B-2

     

    

9.            Confidentiality.
You agree that the existence and terms and conditions of this Agreement (other than Exhibit A) shall remain confidential and
that you will not disclose any information concerning the provisions of this Agreement to any person or entity, including, but
not limited to, any present or former employee of ReShape Lifesciences. These confidentiality provisions are subject to the following
exceptions: you may disclose the provisions of this Agreement to your attorneys, accountants, tax and financial advisors, and immediate
family, or in the course of legal proceedings involving ReShape Lifesciences, or in response to a subpoena, court order, or inquiry
by a government agency. You further agree that, if any information concerning the provisions of this Agreement is revealed as permitted
by this section, you shall inform the recipient of the information that it is confidential, and the recipient shall agree to keep
the information confidential.

 

10.           Release.
By this Agreement, you intend to settle any and all claims that you have or may have against ReShape Lifesciences as a result of
ReShape Lifesciences hiring you, your employment with ReShape Lifesciences, and the decision to terminate your employment with
ReShape Lifesciences. You agree that, in exchange for ReShape Lifesciences’ promises in this Agreement, and in exchange for
the consideration provided to you by ReShape Lifesciences, described above in Section 2, you, on behalf of your heirs, successors
and assigns, hereby release and discharge ReShape Lifesciences, its predecessors, successors, assigns, parents, affiliates, subsidiaries,
and related companies, and their officers, directors, shareholders, agents, servants, employees, and insurers (collectively “the
Released Parties”) from all liability for damages and from all claims that you may have against the Released Parties occurring
up through the date you sign this Agreement. You understand and agree that your release of claims in this Agreement includes, but
is not limited to, any claims you may have under: Title VII of the Federal Civil Rights Act of 1964, as amended; the Americans
with Disabilities Act; the Equal Pay Act; the Employee Retirement Income Security Act; the Age Discrimination in Employment Act
of 1967, as amended; the Older Workers Benefit Protection Act; the Family and Medical Leave Act; the Worker Adjustment and Retraining
Notification Act of 1988; the False Claims Act and/or any other local, state, or federal law governing discrimination in employment
and/or the payment of wages and benefits.

 

You also agree and understand that you
are giving up all other claims, whether grounded in contract or tort theories, including but not limited to: wrongful discharge;
breach of contract; any claim for unpaid compensation (including, but not limited to, any claims for PTO or severance except as
set forth in this Agreement, or for incentive compensation); tortious interference with contractual relations; promissory estoppel;
detrimental reliance; breach of the implied covenant of good faith and fair dealing; breach of express or implied promise; breach
of manuals or other policies; breach of fiduciary duty; assault; battery; fraud; false imprisonment; invasion of privacy; intentional
or negligent misrepresentation; defamation, including libel, slander, discharge defamation and self-publication defamation; discharge
in violation of public policy; whistleblower; qui tam actions; intentional or negligent infliction of emotional distress; or any
other theory, whether legal or equitable.

 

You understand that nothing contained in
this Agreement, including but not limited to this Section 10, will be interpreted to prevent you from filing a charge with
the Equal Employment Opportunity Commission (“EEOC”), or any other governmental agency or from participating in or
cooperating with an EEOC or other governmental agency investigation or proceeding.

 

    B-3

     

    

However, you agree that you are waiving the right to monetary
damages or other individual legal or equitable relief awarded as a result of any such proceeding.

 

11.           Time
to Accept. You are hereby informed that the terms of this Agreement shall be open for acceptance and execution by you through
and including                           , during which time
you may consult with an attorney and consider whether to accept this Agreement. Changes to this Agreement, whether material or
immaterial, will not restart the running of this acceptance period. You hereby are advised to consult with an attorney prior to
signing this Agreement.

 

12.         Consideration
and Revocation Period. You are hereby informed of your right to revoke your release of claims, insofar as it extends to potential
claims under the Age Discrimination in Employment Act, by informing ReShape Lifesciences of your intent to revoke your release
of claims within 7 calendar days following your signing of this Agreement. You are also informed of your right to rescind your
release of claims, insofar as it extends to potential claims under the California Human Rights Act, by delivering a written rescission
to ReShape Lifesciences within 15 calendar days after your signing of this Agreement. You understand that any such revocation or
rescission must be made in writing and delivered by hand or by certified mail, return receipt requested, postmarked on or before
the last day within the applicable revocation period to: Erica Charlton, HR Payroll Specialist, ReShape Lifesciences, Inc.,
1001 Calle Amanecer, CA 92673. If you exercise your right to revoke or rescind this Agreement, ReShape Lifesciences may, at its
option, either nullify this Agreement in its entirety, or keep it in effect in all respects other than as to that portion of your
release of claims that you have revoked or rescinded. You agree and understand that if ReShape Lifesciences chooses to nullify
the Agreement in its entirety, ReShape Lifesciences will have no obligations under this Agreement to you or to others whose rights
derive from you.

 

13.           Entire
Agreement. This Agreement, as well as the exhibits hereto and any agreements referenced herein, is the final, complete and
exclusive agreement of the parties and sets forth the entire agreement between ReShape Lifesciences and you with respect to your
employment by ReShape Lifesciences, and there are no undertakings, covenants or commitments other than as set forth herein. The
Agreement may not be altered or amended, except by a writing executed by you and a member of the Board. Except as otherwise indicated,
this Agreement supersedes, terminates, replaces and supplants any and all prior understandings or agreements between the parties
relating in any way to you hiring or employment by ReShape Lifesciences.

 

14.           Governing
Law. The laws of the State of California will govern the validity, construction and performance of this Agreement, without
regard to the conflict of law provisions of any other jurisdictions. If any part of this Agreement is construed to be in violation
of any law, such part shall be modified to achieve the objective of the parties to the fullest extent permitted and the balance
of this Agreement shall remain in full force and effect. If such modification is not possible, said provision will be deemed severable
from the remaining provisions of this Agreement and the balance of this Agreement shall remain in full force and effect.

 

15.           Remedies.
Any disputes with regard to this Agreement will be governed by the Arbitration Agreement in Section 4.5 of your Employment
Agreement.

 

    B-4

     

    

16.        Non-Disparagement/Litigation
Assistance. You agree to refrain from any disparagement of the Company, including to the Company’s owners, former and
current employees to members of the public. You further agree not to commence, maintain, prosecute or participate in (except as
may be required by law, pursuant to court order, or in response to a valid subpoena) any action, charge, complaint, or proceeding
of any kind (on your own behalf and/or on behalf of any other person or entity and/or on behalf of or as a member of any alleged
class of persons) in any court, or before any administrative or investigative body or agency (whether public, quasi-public or private)
against the Company or any Released Party with respect to any act, omission, transaction or occurrence arising out of your employment
at the Company.

 

17.         No
Admission. Nothing in this Agreement is intended to be, and nothing will be deemed to be, an admission of liability by ReShape
Lifesciences or you that either party has violated any state or federal statute, local ordinance or principle of common law, or
that either party has engaged in any wrongdoing.

 

18.           Waiver.
No waiver of any provision of this Agreement shall be binding unless executed in writing by the party making the waiver. The waiver
by either party of a breach by the other party of any provision of this Agreement shall not operate or be construed as a waiver
of any subsequent breach.

 

IN WITNESS WHEREOF,
the parties have duly executed this Agreement on the dates set forth below to be effective as of the date shown below.

 

I acknowledge and agree that I have
read this Agreement in its entirety and that I agree to the conditions and obligations set forth herein. Further, I agree
that I have had adequate time to consider the terms of this Agreement and that I am voluntarily entering into this Agreement with
a full understanding of its meaning. I understand that I am hereby advised to consult with an attorney before signing this Agreement.

 

	Dated:	 	 	 
	 	Thomas Stankovich
	 
	 	RESHAPE LIFESCIENCES INC.
	 
	Dated:	 	 	By:	 
	 	 	 	 	 
	 	Its:	 

 

    B-5Exhibit 4.1

  

  
    

    

    Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

  

  
    

    

    As of March 25, 2021, Dream Finders Homes, Inc., a Delaware corporation (the “Company”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):
      Class A common stock, par value $0.01 per share (“Class A common stock”). The following contains a description of our Class A common stock, as well as certain related additional information. This description is a summary only and does not purport to
      be complete. We encourage you to read the complete text of the Company’s amended and restated certificate of incorporation (our “Amended and Restated Certificate of Incorporation”) and amended and restated bylaws (“Amended and Restated Bylaws”),
      which we have incorporated by reference as exhibits to the Company’s Annual Report on Form 10-K. References to “we,” “our” and “us” refer to the Company, unless the context otherwise requires. References to “stockholders” refer to holders of our
      Class A common stock and our Class B common stock, par value $0.01 per share (“Class B common stock”).

  

  
    

    

    General

  

  
    

    

    Pursuant to the Company’s Amended and Restated Certificate of Incorporation, the total number of shares of capital stock that the Company has authority to issue is 355,000,000 shares consisting of: (i) 289,000,000 shares
      of Class A common stock, of which 32,295,329 shares were issued and outstanding as of March 25, 2021; (ii) 61,000,000 shares of Class B common stock, of which 60,226,153 shares were issued and outstanding as of March 25, 2021; and (iii) 5,000,000
      shares of preferred stock, par value $0.01 per share (“Preferred Stock”), of which no shares were issued and outstanding as of March 25, 2021.  The Class A common stock and Class B common stock shall hereinafter collectively be referred to as “common
      stock.” The board of directors of the Company (the “Board of Directors”) is authorized, without stockholder approval, except as required by Nasdaq Global Select Market (“Nasdaq”) listing standards, to issue additional shares of our capital stock.

     

    

  

  Class A Common Stock and Class B Common Stock

  

  

  Except with respect to voting, transfer and conversion rights as described below and as otherwise expressly provided in our Amended and Restated Certificate of Incorporation or required by applicable law, shares of our
    Class A common stock and Class B common stock have the same rights and privileges and rank equally, share ratably and are identical in all respects as to all matters.

  

  

  Voting Rights

  

  

  Holders of our Class A common stock are entitled to one vote per share on any matter that is submitted to a vote of our stockholders. Holders of our Class B common stock are entitled to three votes per share on any matter
    that is submitted to a vote of our stockholders. Holders of shares of Class A common stock and Class B common stock vote together as a single class on all matters (including the election of directors) submitted to a vote of stockholders, unless
    otherwise required by Delaware law.

  

  

  Under Delaware law, holders of our Class A common stock or Class B common stock are entitled to vote as a separate class if a proposed amendment to our Amended and Restated Certificate of Incorporation would increase or
    decrease the aggregate number of authorized shares of such class, increase or decrease the par value of the shares of such class or alter or change the powers, preferences or special rights of the shares of such class so as to affect them adversely. As
    a result, in these limited instances, the holders of a majority of the Class A common stock could defeat any amendment to our Amended and Restated Certificate of Incorporation. For example, if a proposed amendment to our Amended and Restated
    Certificate of Incorporation provided for the Class A common stock to rank junior to the Class B common stock with respect to (1) any dividend or distribution, (2) the distribution of proceeds were we to be acquired or (3) any other right, Delaware law
    would require the vote of the holders of the Class A common stock. In this instance, the holders of a majority of Class A common stock could defeat that amendment to our Amended and Restated Certificate of Incorporation.

   

  

  
    
      

  

  Our Amended and Restated Certificate of Incorporation does not provide for cumulative voting for the election of directors.

  

  

  Economic Rights

  

  

  Except as otherwise expressly provided in our Amended and Restated Certificate of Incorporation, all shares of Class A common stock and Class B common stock have the same rights and privileges and rank equally, share
    ratably and be identical in all respects for all matters, including those described below.

  

  

  Dividends and Distributions

  

  

  Subject to preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of Class A common stock and Class B common stock are entitled to share equally, identically and ratably, on a per
    share basis, with respect to any dividend or distribution of cash or property paid or distributed by us, unless different treatment of the shares of the affected class is approved by the affirmative vote of the holders of a majority of the outstanding
    shares of such affected class, voting separately as a class.

  

  

  Liquidation Rights

  

  

  On our liquidation, dissolution or winding-up, the holders of Class A common stock and Class B common stock will be entitled to share equally, identically and ratably in all assets remaining after the payment of any
    liabilities, liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any outstanding Preferred Stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding
    shares of such affected class, voting separately as a class.

  

  

  Change of Control Transactions

  

  

  The holders of Class A common stock and Class B common stock are treated equally and identically with respect to shares of Class A common stock or Class B common stock owned by them, unless different treatment of the
    shares of each class is approved by the affirmative vote of the holders of a majority of the outstanding shares of the class treated differently, voting separately as a class, on (a) the closing of the sale, transfer or other disposition of all or
    substantially all of our assets, (b) the consummation of a consolidation, merger or reorganization which results in our voting securities outstanding immediately before the transaction (or the voting securities issued with respect to our voting
    securities outstanding immediately before the transaction) representing less than a majority of the combined voting power of our voting securities or the surviving or acquiring entity or (c) the closing of the transfer (whether by merger, consolidation
    or otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons of our securities if, after closing, the transferee person or group would hold 50% or more of the outstanding voting power of our voting
    securities (or the surviving or acquiring entity). However, consideration to be paid or received by a holder of our common stock in connection with any such assets sale, consolidation, merger or reorganization under any employment, consulting,
    severance or other compensatory arrangement will be disregarded for the purposes of determining whether holders of our common stock are treated equally and identically.

  

  

  Subdivisions and Combinations

  

  

  If we subdivide or combine in any manner outstanding shares of Class A common stock or Class B common stock, the outstanding shares of the other classes will be subdivided or combined in the same proportion and manner.

   

  

  
    
      

  

  No Preemptive or Similar Rights

  

  

  Our Class A common stock and Class B common stock are not entitled to preemptive rights and are not subject to conversion, redemption or sinking fund provisions, except for the conversion provisions with respect to the
    Class B common stock described below.

  

  

  Conversion

  

  

  Each share of Class B common stock is convertible at any time at the option of the holder of Class B common stock into one share of Class A common stock. Upon any transfer of shares of Class B common stock, whether or not
    for value, each such transferred share will automatically convert into one share of Class A common stock, except for certain transfers described in our Amended and Restated Certificate of Incorporation, including (i) the pledge of shares of Class B
    common stock that creates a security interest in such shares, so long as the pledging holder continues to exercise voting control over such pledged shares; (ii) the entry into a Rule 10b5-1 trading plan with a broker or other nominee where the holder
    retains voting control over the shares; (iii) the entry into a support or similar agreement in connection with certain specified events; (iv) the transfer of Class B common stock to an existing holder of Class B common stock; and (v) the transfer of
    shares of Class B common stock to any trust or other entity for tax and estate planning purposes, so long as a holder of Class B common stock controls the entity. Once transferred and converted into Class A common stock, the Class B common stock may
    not be reissued.

  

  

  Further, all of the shares of our Class B common stock will automatically convert into shares of Class A common stock upon the date when our President and Chief Executive Officer, Mr. Patrick O. Zalupski, and permitted
    transferees of our Class B common stock cease to hold shares of Class B common stock representing, in the aggregate, at least 10% or more of the total number of shares of Class A common stock and Class B common stock issued and outstanding.

  

  

  Each share of Class A common stock is not convertible into any other shares of our capital stock.

  

  

  Fully Paid and Non-Assessable

  

  

  As of March 25, 2021 all of the issued and outstanding shares of our Class A common stock are fully paid and non-assessable.

  

  

  Preferred Stock

  

  

  Our Board of Directors has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be
    included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series,
    but not below the number of shares of such series then outstanding.

  

  

  Our Board of Directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of
    authorizing our Board of Directors to issue Preferred Stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of Preferred Stock, while providing flexibility in
    connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our common stock and the voting and
    other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of Preferred Stock on the rights of holders of our common stock until our Board of Directors determines the specific rights
    attached to such Preferred Stock.

   

  

  Anti-Takeover Effects of Provisions of our Certificate of Incorporation, our Bylaws and Delaware Law

  

  

  Some provisions of Delaware law, and our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws described below, contain provisions that could make the following transactions more difficult:
    acquisitions of us by means of a tender offer, a proxy contest or otherwise; or removal of our incumbent officers and directors. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions
    could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our
    shares.

  

  

  
    
      

  

  Section 203 of the Delaware General Corporation Law

  

  

  In general, Section 203 of the General Corporation Law of the State of Delaware (the “DGCL”) prohibits a publicly held Delaware corporation from engaging in a business combination,
    such as a merger, sale or lease of assets, issuance of securities or similar transaction by a corporation or subsidiary with an interested stockholder, including a person or group who beneficially owns 15% or more of the corporation’s voting stock, for
    a period of three years following the date the person became an interested stockholder, unless (with certain exceptions) the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed
    manner. Section 203 of the DGCL permits corporations, in their certificate of incorporation, to opt out of the protections of Section 203 of the DGCL. Our Amended and Restated Certificate of Incorporation provides that we have elected not to be subject
    to Section 203 of the DGCL for so long as Mr. Zalupski owns, directly or indirectly, at least 10% of the outstanding shares of our common stock. From and after the date that Mr. Zalupski ceases to own, directly or indirectly, at least 10% of the
    outstanding shares of our common stock, we will be governed by Section 203 of the DGCL.

  

  

  Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

  

  

  No Cumulative Voting Rights

  

  

  Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of common stock are able to elect all of our directors.

  

  

  Stockholder Action by Written Consent; Special Meetings of Stockholders

  

  

  The DGCL permits stockholder action by written consent unless otherwise provided by our Amended and Restated Certificate of Incorporation. Our Amended and Restated Certificate of Incorporation and Amended and Restated
    Bylaws provides for stockholder actions at a duly called meeting of stockholders or, until such time as we no longer qualify as a controlled company under Nasdaq rules, by written consent. Our Amended and Restated Bylaws provide that special meetings
    of our stockholders may be called only by our Board of Directors or by stockholders owning at least 25% in amount of our entire capital stock issued and outstanding and entitled to vote on the election of directors.

  

  

  Requirements for Advance Notification of Stockholder Nominations and Proposals

  

  

  Our Amended and Restated Bylaws establish advance notice procedures with respect to stockholder proposals, other than proposals made by or at the direction of our Board of Directors. Our Amended and Restated Bylaws
    establish advance notice procedures with respect to the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board of Directors or by a committee appointed by our Board of Directors.

  

  

  Issuance of Undesignated Preferred Stock

  

  

  Our Amended and Restated Certificate of Incorporation authorizes our Board of Directors, without further action by our stockholders, to issue shares of Preferred Stock in one or more series, and with respect to each
    series, to fix the number of shares constituting that series and to establish the rights and other terms of that series.

  

  

  Number of Directors and Filling Vacancies

  

  

  Our Amended and Restated Certificate of Incorporation provides that the number of directors is established by our Board of Directors, subject to a minimum of three members. In accordance with our Amended and Restated
    Bylaws, as of March 25, 2021, our Board of Directors consists of five members. In addition, vacancies on our Board of Directors or newly created directorships resulting from an increase in the number of our directors may be filled only by a majority of
    directors then in office, even though less than a quorum.

   

  

  
    
      

  

  Amendment of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

  

  

  Our Amended and Restated Certificate of Incorporation provides that our Amended and Restated Certificate of Incorporation may be amended by the affirmative vote of a majority of our Board of Directors. In addition, our
    Amended and Restated Bylaws may be amended by the affirmative vote of a majority of our Board of Directors without stockholder approval.

  

  

  The foregoing provisions will make it more difficult for another party to obtain control of us by replacing our Board of Directors. Since our Board of Directors has the power to retain and discharge our officers, these
    provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated Preferred Stock makes it possible for our Board of Directors to issue Preferred
    Stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

  

  

  Forum Selection

  

  

  Our Amended and Restated Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternate forum, the Court of Chancery of the State of Delaware will, to the fullest extent provided
    by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed to us or our stockholders by any of our directors, officers, other
    employees, agents or stockholders; (iii) any action asserting a claim against us arising under the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware (including, without limitation, any action asserting
    a claim arising out of or pursuant to our Amended and Restated Bylaws); or (iv) any action asserting a claim against us that is governed by the internal affairs doctrine, in each case subject to such Court of Chancery of the State of Delaware having
    personal jurisdiction over the indispensable parties named as defendants. Additionally, our Amended and Restated Certificate of Incorporation states that the foregoing provision will not apply to claims subject to exclusive jurisdiction in the federal
    courts, such as suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the “Securities Act”), the Exchange Act or the rules and regulations thereunder. Our Amended and Restated Certificate of Incorporation
    provides that, unless we consent in writing to the selection of an alternate forum, the federal district courts of the United States will, to the fullest extent provided by law, be the sole and exclusive forum for the resolution of any complaint
    asserting a cause of action arising under the Securities Act. Although our Amended and Restated Certificate of Incorporation contains the exclusive forum provisions described above, it is possible that a court could find that such provisions are
    inapplicable for a particular claim or action or that such provisions are unenforceable, and our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. All of our
    stockholders are deemed to have notice of, and have consented to, the provisions of our Amended and Restated Certificate of Incorporation related to choice of forum.

  

  

  Limitations of Liability and Indemnification

  

  

  Our Amended and Restated Certificate of Incorporation limits the liability of our directors for monetary damages for breach of their fiduciary duty as our directors, except for liability that cannot be eliminated under the
    DGCL. The DGCL provides that directors of a company will not be personally liable for monetary damages for breach of their fiduciary duty as directors, except for liabilities:

   

  

  
    
      	 	
              •

            	
              for any breach of their duty of loyalty to such company or its stockholders;

            

    

  

  

  

  	 	•	
          for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

        

  

  

  	 	•	
          for unlawful payment of dividends or unlawful stock repurchases or redemptions, as provided under Section 174 of the DGCL; or

        

   

  	 	•	
          for any transaction from which the director derived an improper personal benefit.

        

   

  

  
    
      

  

  Any amendment, repeal or modification of these provisions of the DGCL will be prospective only and would not affect any limitation on liability of one of our directors for acts or omissions that occurred prior to any such
    amendment, repeal or modification.

  

  

  Our Amended and Restated Bylaws also provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. Our Amended and Restated Bylaws also permit us to purchase insurance on behalf
    of any officer, director, employee or other agent for any liability arising out of that person’s actions as our officer, director, employee or agent, regardless of whether Delaware law would permit indemnification.

  

  

  We have also entered into indemnification agreements with each of our directors and officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liability
    that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

  

  

  Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion
    of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

  

  

  Registration Rights

  

  

  We entered into a registration rights agreement (the “Registration Rights Agreement”) with Mr. Zalupski, POZ Holdings, Inc., an entity Mr. Zalupski controls, BOC DFH, LLC, W. Radford Lovett II and certain members of our
    management (collectively, the “Registration Rights Parties”). The Registration Rights Agreement provides Mr. Zalupski with the right to request certain “demand” registrations with respect to his combined personal holdings and shares held by POZ
    Holdings, Inc. The Registration Rights Agreement also provides the Registration Rights Parties with customary “piggyback” registration rights. The Registration Rights Agreement contains provisions for the coordination by the Registration Rights Parties
    of their sales of shares of our Class A common stock and contains certain limitations on the ability of the members of our management party to the Registration Rights Agreement to offer, sell or otherwise dispose of shares of our Class A common stock.
    The Registration Rights Agreement also provides that we will pay certain expenses of the Registration Rights Parties relating to such registrations and indemnify them against certain liabilities that may arise under the Securities Act.

  

  

  Transfer Agent and Registrar

  

  

  The transfer agent and registrar for our Class A common stock and Class B common stock is Broadridge Corporate Issuer Solutions, Inc.

  

  

  Listing

  
    

    

    Our Class A common stock is listed on the Nasdaq Global Select Market under the symbol “DFH.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]